Navigation Links
Smokers may differ in their cravings for smoking

A brain scan study of the smokers reveals that the smokers may differ in their cravings// for a smoke depending on their brain’s sensitivity to smoking.

Researchers have found that the urge to smoke after a period of abstinence will vary in smokers according to the brain responses to the smoking habit. Researchers from the Duke University Medical Center had looked into the brain images of smokers in a bid to study the differential responses to quitting smoking.

Although nicotine cravings are considered to be at the root of not being able to quit smoking, recent research suggests that conditioned response to various sensory cues like presentation of visuals, or smelling of tobacco can also set the stage of continuous smoking for smokers who are not able to quit. In the new research scientists have found that those who can abstain from smoking for long hours, even after viewing smoking related visuals, showed more stable brain responses than the other smokers who felt the urge to smoke on seeing the same visuals.

The research suggests that people may differ in their tendencies to react to drugs, as their brain views the sensory cues differently. The researchers feel that this discovery may lead to differential use of quitting procedures for smokers depending on their brain responses.

Reference: Neuropsychopharmacology, online edition, June 2005
'"/>




Page: 1

Related medicine news :

1. Smokers children likely to develop caries
2. Smokers more prone to depression
3. Female Smokers More Prone To Lung Cancer
4. Young Smokers at Increased Risk Of Developing a Heart Attack
5. Women Smokers More Prone To Lung Cancer
6. Creating A Greater Awareness Among Smokers
7. Trained Counselors Counseling Pregnant Smokers To Quit May Not Work
8. Smokers Avoid Dental Care More Than Others
9. Smokers Face The Risk Of Becoming Blind In Later Life
10. New Vaccination For Smokers To Quit Smoking
11. B-Carotene Increases Oral Cancer Risk In Smokers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2017)... VA (PRWEB) , ... March 27, 2017 , ... ... application containerization, today announced it will co-exhibit with technology partners LG Business Solutions ... at the Marriott Metro Center in Washington D.C., will provide education and examination ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... the CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds ... highest industry standards and specifications such as ANSI, ISO and proven test methods ...
(Date:3/27/2017)... ... 2017 , ... Osteitis pubis may be commonplace and seemingly ... occurs when the muscles around the pelvis become inflamed. Over time, untreated osteitis ... as well as accompanying tenderness and weakness. Without proper intervention, it can hinder ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek , a Farmingdale, ... recent RNA methylation “gold rush” with their established portfolio of optimized assay kits ... N6-methyladenosine, or m6A , RNA methylation has received a new burst in ...
(Date:3/27/2017)... San Mateo, CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still ... one of the best days I’ve had in a long time,” she said. , She ... a lot of money that I never thought I would have to help my students.” ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Pulmatrix, Inc . (NASDAQ: PULM), a clinical stage biopharmaceutical company ... announced that it has added two experts in the fields ... Scientific Advisory Board . The two experts ... MD, former chief of the Pediatric Pulmonary and Allergy Divisions ... University, and David Denning , MD, ...
(Date:3/27/2017)... SAN FRANCISCO , March 27, 2017 ...  is expected to reach USD 16.0 billion by 2025, ... Inc. The growing prevalence of chronic diseases is anticipated ... clinical chemistry analyzers, which thereby widens the scope for ... of geriatric and bariatric population, which is highly susceptible ...
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
Breaking Medicine Technology: